Type
|
Public |
---|---|
Traded as | NYSE: AET S&P 500 Component |
Industry | Managed health care |
Founded | May 28, 1853 (1853-05-28) (as Aetna Life Insurance Company) |
Founder | Eliphalet Adams Bulkeley |
Headquarters | 151 Farmington Ave, Hartford, Connecticut, 06105 U.S. |
Area served
|
United States |
Key people
|
Mark T. Bertolini (Chairman and CEO) Karen S. Lynch (President) |
Products | Healthcare plans |
Revenue | $ 63.175 billion (FY 2016) |
Operating income
|
$ 2.917 billion (FY 2016) |
Net income
|
$ 2.271 billion (FY 2016) |
Total assets | $ 2.271 billion (FY 2016) |
Total equity | $ 17.943 billion (FY 2016) |
Number of employees
|
49,500 (FY 2016) |
Website | www |
Aetna Inc. (/ˈɛtnə/; stylized as ætna) is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.
In June 2017, the company announced plans to move its headquarters to New York City in late 2018.
Aetna offers health care, dental, pharmacy, group life, disability, and long-term care insurance and employee benefits, primarily through employer-paid (fully or partly) insurance and benefit programs, and through Medicare. Membership numbers: (as of September 30, 2016)
Aetna has spent more than $2.0 million in 2009 on lobbying. The company spent $809,793 between January 2009 and the end of March 2009—up 41 percent from the same period in 2008. Aetna's campaign contributions include more than $110,000 to US Senator Joe Lieberman (ID-CT) in 2009. From 2005 through 2009, Aetna contributed $56,250 to Senator Max Baucus (D-MT), chairman of the Senate Finance Committee, making Aetna the senator's seventh highest contributor over that time period.
In the California Health Care Quality Report Card 2011 Edition, Aetna received 2 out of 4 stars in Meeting National Standards of Care and 1 out of 4 in Members Rate Their HMO. In the California Health Care Quality Report Card 2010 Edition, Aetna received 3 out of 4 stars in both Meeting National Standards of Care and How Members Rate Their HMO, for a rating of "Good" (out of "Poor, " "Fair, " "Good, " or "Excellent").
As of 2017 Aetna shares are mainly held by institutional investors (BlackRock, The Vanguard Group, State Street Corporation, T. Rowe Price, Capital Group Companies and others)
Aetna is the direct descendant of Aetna (Fire) Insurance Company, of Hartford, Connecticut. The name was meant to invoke Mount Etna, at the time Europe's most active volcano.
In June 2012, Aetna and Inova Health System announced a joint venture creating a new health insurance company, Innovation Health.
On July 3, 2015, Aetna announced that it planned to acquire Humana for US$37,000,000,000 in cash and stock, or US$230 a share. Aetna and Humana shareholders would have owned 74% and 26% of the new combined company. The acquisition was subject to United States government approval and was expected to close in late 2016.
On January 23, 2017, a federal judge blocked Aetna's merger with Humana, saying it would leave senior citizens with fewer options for Medicare coverage. On February 14, 2017, Aetna Inc. and Humana Inc. officially quashed a $34 billion merger agreement, after judges ruled against the merger for a second time.
On June 29, 2017, Aetna announced the company would be moving their main offices to New York City after being headquartered in Hartford since 1819. The moved will be completed in late 2018.
In 2000 Deadria Farmer-Paellmann, head of the nonprofit Restitution Study Group of Hoboken, New Jersey, disclosed that from approximately 1853 to approximately 1860 Aetna had issued life insurance policies to slaveowners covering the lives of their slaves.
Aetna acknowledged that concrete evidence exists for Aetna issuing coverage for the lives of slaves and released a public apology.
In 2002, Farmer-Paellmann brought suit against Aetna and two other companies in federal court asking for reparations for the descendants of slaves. The lawsuit said Aetna, CSX and Fleet were "unjustly enriched" by "a system that enslaved, tortured, starved and exploited human beings." It argued that African-Americans are still suffering the effects of 2½ centuries of enslavement followed by more than a century of institutionalized racism. The complaint blamed slavery for present-day disparities between blacks and whites in income, education, literacy, health, life expectancy and crime.
This suit was denied, and the denial largely upheld on appeal.
In 2006, Farmer-Paellmann announced a nationwide boycott of Aetna over the issue of reparations for its policies covering slaves. Aetna stated that its commitment to diversity in the workplace and its investment of over 36 million dollars in such areas as education, health, economic development, community partnerships, and minority-owned business initiatives in the African-American community are more effective at aiding descendants of slaves and African-Americans in general than making restitutions for Aetna's life insurance policies on slaves.
2016-07-10 | Reiterated Rating | Credit Suisse Group AG | Neutral to Hold | |
2016-06-29 | Reiterated Rating | Credit Suisse | Hold | $120.00 |
2016-06-29 | Reiterated Rating | Credit Suisse Group AG | Hold | $120.00 |
2016-06-28 | Initiated Coverage | Wolfe Research | Outperform | $154.00 |
2016-06-21 | Reiterated Rating | Leerink Swann | Outperform | |
2016-06-16 | Initiated Coverage | Sanford C. Bernstein | Outperform | $142.00 |
2016-06-14 | Reiterated Rating | Morgan Stanley | Buy | |
2016-06-02 | Reiterated Rating | Wells Fargo | Buy | |
2016-06-02 | Reiterated Rating | Wells Fargo & Co. | Buy | |
2016-05-16 | Reiterated Rating | Sterne Agee CRT | Buy | |
2016-04-30 | Reiterated Rating | Morgan Stanley | Buy | |
2016-04-29 | Reiterated Rating | FBR & Co. | Hold | $135.00 |
2016-04-29 | Boost Price Target | RBC Capital | Outperform | $140.00 to $144.00 |
2016-04-29 | Reiterated Rating | FBR & Co | Hold | $135.00 |
2016-04-29 | Boost Price Target | Royal Bank Of Canada | Outperform | $140.00 to $144.00 |
2016-04-08 | Initiated Coverage | Cleveland Research | Neutral | $120.00 |
2016-04-05 | Reiterated Rating | Leerink Swann | Outperform | |
2016-04-05 | Reiterated Rating | Cowen and Company | Outperform | |
2016-02-19 | Reiterated Rating | Wells Fargo | Buy | |
2016-02-03 | Boost Price Target | BMO Capital Markets | Outperform | $128.00 to $129.00 |
2016-02-02 | Reiterated Rating | FBR & Co. | Market Perform | $135.00 |
2016-02-02 | Lower Price Target | Jefferies Group | Hold | $122.00 to $118.00 |
2016-02-02 | Lower Price Target | Wedbush | Neutral | $130.00 to $120.00 |
2016-02-02 | Reiterated Rating | Oppenheimer | Market Perform | |
2016-02-02 | Lower Price Target | RBC Capital | Outperform | $142.00 to $140.00 |
2016-02-02 | Reiterated Rating | Cantor Fitzgerald | Buy | $140.00 |
2016-02-02 | Reiterated Rating | Oppenheimer Holdings Inc. | Market Perform | |
2016-01-08 | Downgrade | Jefferies Group | Buy to Hold | $135.00 to $122.00 |
2015-12-17 | Reiterated Rating | Credit Suisse | Hold | |
2015-12-16 | Initiated Coverage | Credit Suisse | Neutral | $111.00 |
2015-11-23 | Reiterated Rating | Leerink Swann | Outperform | |
2015-10-30 | Lower Price Target | RBC Capital | $162.00 to $146.00 | |
2015-10-30 | Lower Price Target | JPMorgan Chase & Co. | $144.00 to $141.00 | |
2015-10-30 | Reiterated Rating | Leerink Swann | Buy | $160.00 |
2015-09-18 | Upgrade | Cantor Fitzgerald | Hold to Buy | $100.00 to $140.00 |
2015-09-16 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $144.00 |
2015-09-08 | Upgrade | RBC Capital | Sector Perform to Outperform | $159.00 to $162.00 |
2015-08-13 | Reiterated Rating | Jefferies Group | Buy | $135.00 |
2015-08-05 | Reiterated Rating | Oppenheimer | Hold | |
2015-08-04 | Reiterated Rating | Leerink Swann | Buy | |
2015-08-04 | Reiterated Rating | Sterne Agee CRT | Buy | $134.00 |
2015-08-04 | Reiterated Rating | Susquehanna | Buy | $135.00 |
2015-07-30 | Upgrade | Bank of America | Neutral to Buy | $132.00 |
2015-07-30 | Upgrade | Bank of America Corp. | Neutral to Buy | $132.00 |
2015-07-08 | Reiterated Rating | Barclays | Buy | |
2015-07-08 | Reiterated Rating | Barclays PLC | Buy | |
2015-07-07 | Reiterated Rating | S&P Equity Research | Strong-Buy | $150.00 |
2015-07-06 | Reiterated Rating | Cowen and Company | Buy | $145.00 |
2015-07-06 | Boost Price Target | Barclays | Overweight | $125.00 to $152.00 |
2015-07-06 | Boost Price Target | Leerink Swann | Outperform | $150.00 to $160.00 |
2015-07-06 | Downgrade | FBR & Co. | Outperform to Market Perform | $120.00 to $130.00 |
2015-06-28 | Reiterated Rating | Leerink Swann | Buy | |
2015-06-26 | Boost Price Target | Leerink Swann | Outperform | $145.00 to $150.00 |
2015-06-24 | Initiated Coverage | RBC Capital | Sector Perform | $159.00 |
2015-06-17 | Reiterated Rating | Deutsche Bank | Buy | $122.00 to $135.00 |
2015-06-17 | Reiterated Rating | Leerink Swann | Outperform to Outperform | $135.00 to $145.00 |
2015-06-17 | Reiterated Rating | Deutsche Bank AG | Buy | $122.00 to $135.00 |
2015-05-23 | Reiterated Rating | Leerink Swann | Outperform | $130.00 to $135.00 |
2015-05-13 | Reiterated Rating | Deutsche Bank | Buy | $122.00 |
2015-05-12 | Boost Price Target | Leerink Swann | Outperform | $130.00 to $135.00 |
2015-05-04 | Reiterated Rating | BMO Capital Markets | Outperform | $119.00 to $122.00 |
2015-04-29 | Set Price Target | Leerink Swann | Buy | $125.00 to $130.00 |
2015-04-29 | Set Price Target | Barclays | Buy | $122.00 to $125.00 |
2015-04-29 | Boost Price Target | Argus | Buy | $115.00 to $130.00 |
2015-03-20 | Set Price Target | Barclays | Buy | $119.00 to $122.00 |
2015-03-19 | Upgrade | Sterne Agee CRT | Neutral to Buy | $96.00 to $124.00 |
2015-03-12 | Boost Price Target | Argus | Buy | $103.00 to $115.00 |
2015-02-24 | Reiterated Rating | Deutsche Bank | Buy | $111.00 |
2015-02-23 | Set Price Target | Credit Suisse | Buy | $112.00 |
2015-02-04 | Reiterated Rating | Oppenheimer | Hold | |
2015-02-04 | Set Price Target | Deutsche Bank | Buy | $104.00 to $106.00 |
2015-02-03 | Boost Price Target | FBR & Co. | Outperform | $99.00 to $105.00 |
2015-01-20 | Boost Price Target | Jefferies Group | Buy | $103.00 to $106.00 |
2015-01-20 | Boost Price Target | Argus | Buy | $95.00 to $103.00 |
2015-01-08 | Boost Price Target | Barclays | Overweight | $96.00 to $104.00 |
2015-01-06 | Reiterated Rating | Deutsche Bank | Buy | $94.00 to $103.00 |
2014-12-22 | Reiterated Rating | Oppenheimer | Hold | |
2014-12-12 | Reiterated | FBR Capital | Outperform | $93 to $99 |
2014-12-12 | Boost Price Target | Credit Suisse | $103.00 | |
2014-12-12 | Reiterated Rating | Citigroup Inc. | Hold | $78.00 to $88.00 |
2014-12-12 | Reiterated Rating | Jefferies Group | Buy | $99.00 to $103.00 |
2014-12-12 | Boost Price Target | Deutsche Bank | Buy | $88.00 to $94.00 |
2014-12-12 | Boost Price Target | Stifel Nicolaus | Buy | $90.00 to $100.00 |
2014-12-12 | Boost Price Target | FBR & Co. | Outperform | $93.00 to $99.00 |
2014-11-18 | Reiterated Rating | Bank of America | Hold | $86.00 to $92.00 |
2014-11-10 | Reiterated Rating | Jefferies Group | Buy | $90.00 to $99.00 |
2014-10-29 | Reiterated Rating | Deutsche Bank | Buy | $92.00 to $88.00 |
2014-10-29 | Reiterated Rating | Citigroup Inc. | Neutral | $73.00 to $78.00 |
2014-10-29 | Reiterated Rating | Barclays | Overweight | $95.00 to $96.00 |
2014-10-03 | Upgrade | Argus | Hold to Buy | $95.00 |
2014-09-22 | Downgrade | Bank of America | Buy to Neutral | |
2014-08-07 | Downgrade | Goldman Sachs | Buy to Neutral | $94.00 to $88.00 |
2014-08-07 | Downgrade | Goldman Sachs Group Inc. | Buy to Neutral | $94.00 to $88.00 |
2014-07-31 | Boost Price Target | Leerink Swann | Outperform | $83.00 to $90.00 |
2014-07-30 | Reiterated Rating | Barclays | Overweight | $87.00 to $95.00 |
2014-07-29 | Boost Price Target | FBR & Co. | Outperform | $80.00 to $93.00 |
2014-07-16 | Reiterated Rating | Deutsche Bank | Buy | $85.00 to $92.00 |
2014-07-14 | Boost Price Target | Susquehanna | $90.00 to $95.00 | |
2014-07-10 | Reiterated Rating | Jefferies Group | Buy | $89.00 to $94.00 |
2014-06-27 | Initiated Coverage | Sterne Agee CRT | Neutral | $87.00 |
2014-06-18 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $81.00 to $82.00 |
2014-06-03 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $78.00 to $81.00 |
2014-06-02 | Boost Price Target | Cantor Fitzgerald | Hold | $75.00 to $85.00 |
2014-05-30 | Boost Price Target | Cowen and Company | $76.00 to $87.00 | |
2014-05-13 | Reiterated Rating | Morgan Stanley | Overweight | $83.00 |
2014-04-25 | Boost Price Target | Barclays | Overweight | $80.00 to $87.00 |
2014-04-25 | Boost Price Target | Susquehanna | $85.00 to $90.00 | |
2014-04-25 | Downgrade | Citigroup Inc. | Buy to Neutral | $73.00 |
2014-04-25 | Boost Price Target | Jefferies Group | $87.00 to $89.00 | |
2014-04-10 | Boost Price Target | Susquehanna | Positive | $80.00 to $85.00 |
2014-04-03 | Boost Price Target | Deutsche Bank | Buy | $76.00 to $84.00 |
2014-03-12 | Reiterated | UBS | Buy | $82 to $86 |
2014-03-07 | Boost Price Target | Jefferies Group | Buy | $87.00 |
2014-02-10 | Boost Price Target | Cantor Fitzgerald | $75.00 | |
2014-02-06 | Upgrade | Leerink Swann | Market Perform to Outperform | |
2014-01-09 | Upgrade | Credit Suisse | Neutral to Outperform | $69.00 to $83.00 |
2014-01-08 | Boost Price Target | Barclays | Overweight | $75.00 to $80.00 |
2013-12-13 | Boost Price Target | FBR & Co. | Outperform | $71.00 to $75.00 |
2013-12-13 | Reiterated Rating | Morgan Stanley | Overweight | $83.00 |
2013-11-25 | Reiterated | UBS | Buy | $76 to $82 |
2013-11-21 | Initiated Coverage | Morgan Stanley | Overweight | $83.00 |
2013-11-19 | Initiated Coverage | Leerink Swann | Outperform to Market Perform | $72.00 |
2013-11-13 | Initiated Coverage | FBR & Co. | Outperform | |
2013-11-05 | Downgrade | Monness Crespi & Hardt | Buy to Neutral | |
2013-10-30 | Lower Price Target | Deutsche Bank | Buy | $79.00 to $73.00 |
2013-10-30 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $74.00 to $71.00 |
2013-10-30 | Lower Price Target | Barclays | Overweight | $78.00 to $75.00 |
2013-10-30 | Lower Price Target | BMO Capital Markets | Outperform | $70.00 |
2013-10-16 | Boost Price Target | Deutsche Bank | Buy | $72.00 to $79.00 |
2013-10-09 | Reiterated Rating | Susquehanna | Positive | $74.00 to $76.00 |
2013-09-24 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $71.00 to $74.00 |
2013-09-17 | Reiterated | UBS | Buy | $73 to $76 |
2013-09-17 | Reiterated Rating | Cantor Fitzgerald | Hold | $65.00 |
2013-08-06 | Reiterated | Cantor Fitzgerald | Hold | $60 to $65 |
2013-08-01 | Reiterated | UBS | Buy | $68 to $73 |
2013-07-23 | Initiated | Stifel | Buy | $80 |
2013-07-16 | Reiterated | Deutsche Bank | Buy | $68 to $72 |
2013-05-01 | Reiterated | Cantor Fitzgerald | Hold | $55 to $60 |
2013-05-01 | Reiterated | Barclays | Overweight | $57 to $69 |
2013-04-02 | Reiterated | Deutsche Bank | Buy | $55 to $60 |
2016-07-10 | Reiterated Rating | Credit Suisse Group AG | Neutral to Hold | |
2016-06-29 | Reiterated Rating | Credit Suisse | Hold | $120.00 |
2016-06-29 | Reiterated Rating | Credit Suisse Group AG | Hold | $120.00 |
2016-06-28 | Initiated Coverage | Wolfe Research | Outperform | $154.00 |
2016-06-21 | Reiterated Rating | Leerink Swann | Outperform |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In AET 86 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Institutional Trust Company, N.A. | 9.62M |
BLACKROCK ADVISORS LLC | 6.88M |
BlackRock Fund Advisors | 5.71M |
JANUS CAPITAL MANAGEMENT LLC | 4.43M |
BlackRock Group LTD | 4.16M |
BlackRock Investment Management, LLC | 2.94M |
MANAGED ACCOUNT ADVISORS LLC | 0.57M |
RUSSELL FRANK CO/ | 0.47M |
BlackRock Japan Co. Ltd | 0.46M |
RHJ International SA | 0.32M |
Standard Life Investments LTD | 0.27M |
I.G. INVESTMENT MANAGEMENT, LTD. | 0.23M |
COHEN & STEERS CAPITAL MANAGEMENT INC | 0.20M |
DECADE CAPITAL MANAGEMENT LLC | 0.17M |
EverPoint Asset Management, LLC | 0.14M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
Bertolini Mark T Chairman, CEO and President | 32243.79% (114143) | AET / VZ / |
Reisman Lonny SVP, Chief Medical Officer | 24144.07% (85470) | AET / |
Rohan Karen Exec. V.P., Local/Regional Bus | 21157.06% (74896) | AET / USB / |
Casazza William James Sr. VP & General Counsel | 16680.79% (59050) | AET / |
GUERTIN SHAWN M Exec. Vice President, CFO | 13767.51% (48737) | AET / |
HANCOCK ELLEN M | 13324.58% (47169) | AET / CL / |
SOISTMAN FRANCIS S JR Exec. VP, Government Services | 12878.53% (45590) | AET / |
COHEN BETSY Z | 12153.67% (43024) | AET / FNTC / RAS / |
McCarthy Margaret M EVP, Operations & Technology | 10994.35% (38920) | AET / FAF / |
LOVEMAN GARY W EVP, Healthcare Services Bus. | 8881.92% (31442) | AET / COH / CZR / FDX / |
Zubretsky Joseph M Sr. EVP, National Businesses | 7861.58% (27830) | AET / MOH / THG / |
HACKMAN FRANKLIN BARBARA | 6876.84% (24344) | AET / |
SABATINO THOMAS J JR EVP and General Counsel | 6170.06% (21842) | AET / HTZ / IG / WAG / |
CLARK FRANK M | 4609.04% (16316) | AET / WM / |
LUDWIG EDWARD J | 3735.88% (13225) | AET / BSX / XYL / |
GARTEN JEFFREY E | 3110.45% (11011) | AET / KMX / |
AGUIRRE FERNANDO | 2898.59% (10261) | AET / CQB / |
Coye Molly Joel | 2309.04% (8174) | AET / |
HARRINGTON RICHARD J | 2288.14% (8100) | AET / XRX / |
Paz Harold L Exec. VP, Chief Medical Off. | 1672.88% (5922) | AET / SEM / |
NEWHOUSE JOSEPH P | 1148.02% (4064) | AET / |
Parmeswar Rajan VP/Controller/Chief Acct Off | 847.46% (3000) | AET / |
Jelinek Richard M EVP, Enterprise Strategy | 819.21% (2900) | AET / |
SNOWE OLYMPIA J. | 401.13% (1420) | AET / SYF / TROW / |
Virag Sharon VP, Controller & CAO | 39.55% (140) | AES / AET / NEO / |